Publications

FDA likely to see more legal challenges to rulemaking, guidance in 2025

Quoted, BioWorld

Chad Landmon, Chair of the Hatch-Waxman & Biologics practice, discusses why the FDA is likely to face increased legal challenges to its rulemaking and guidance in 2025.